Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes
Vanadium compounds are able to reduce blood glucose in experimentally- induced diabetic rats and type 2 diabetic patients, but data about their long- term safety and efficacy in diabetic patients are scarce. Fourteen type 1 diabetic patients received oral vanadyl sulfate (50 - 100 mg TID) for a peri...
Gespeichert in:
| Veröffentlicht in: | Archives of Iranian medicine 2013-07, Vol.16 (7), p.408 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 408 |
| container_title | Archives of Iranian medicine |
| container_volume | 16 |
| creator | Soveid, Mahmood Dehghani, Gholam Abbas Omrani, Gholamhossein Ranjbar |
| description | Vanadium compounds are able to reduce blood glucose in experimentally- induced diabetic rats and type 2 diabetic patients, but data about their long- term safety and efficacy in diabetic patients are scarce.
Fourteen type 1 diabetic patients received oral vanadyl sulfate (50 - 100 mg TID) for a period of 30 months. Fasting blood sugar (FBS), lipid levels, hematologic, and biochemical parameters were measured before and periodically during the treatment.
The daily doses of insulin decreased from 37.2 ± 5.5 to 25.8 ± 17.3 units/day and at the same time the mean FBS decreased from 238 ± 71 to 152 ± 42 mg/dL. Meanwhile, there was a decrease in plasma total cholesterol without any change in triglyceride level. No significant clinical or paraclinical side effects, with the exception for mild diarrhea at the beginning of treatment, were observed during 30 months therapy.
Vanadium is effective and safe for long- term use in type 1 diabetic patients. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1419400036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3042238421</sourcerecordid><originalsourceid>FETCH-LOGICAL-p206t-7317b97ee977f64999875c6a454a385a08182c52ceb41bfae73c2d7a75511b983</originalsourceid><addsrcrecordid>eNo1T8lKxEAUbERxxtFfkAbPgV7zuo8yuEHQi57DS_JaM5jFTkfI3xtxPFVBFbWcsK0EbTPtDZyuXCifKQ-wYRfTdBDCaCv1Odso7YQDcFv2XAz9e8YTxY5TCG2N9cKxb_iEgdLCh8C_scemnTve9jx9EE-RMHXUp18xLSNxyZsWK0o0XbKzgJ8TXR1xx97u7173j1nx8vC0vy2yUYk8ZaAlVB6I1m0hN957B7bO0ViD2lkUTjpVW1VTZWQVkEDXqgEEa6WsvNM7dvOXO8bha6YplYdhjv1aWUojvRFC6Hx1XR9dc9VRU46x7TAu5f99_QPt4lVb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1419400036</pqid></control><display><type>article</type><title>Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Soveid, Mahmood ; Dehghani, Gholam Abbas ; Omrani, Gholamhossein Ranjbar</creator><creatorcontrib>Soveid, Mahmood ; Dehghani, Gholam Abbas ; Omrani, Gholamhossein Ranjbar</creatorcontrib><description>Vanadium compounds are able to reduce blood glucose in experimentally- induced diabetic rats and type 2 diabetic patients, but data about their long- term safety and efficacy in diabetic patients are scarce.
Fourteen type 1 diabetic patients received oral vanadyl sulfate (50 - 100 mg TID) for a period of 30 months. Fasting blood sugar (FBS), lipid levels, hematologic, and biochemical parameters were measured before and periodically during the treatment.
The daily doses of insulin decreased from 37.2 ± 5.5 to 25.8 ± 17.3 units/day and at the same time the mean FBS decreased from 238 ± 71 to 152 ± 42 mg/dL. Meanwhile, there was a decrease in plasma total cholesterol without any change in triglyceride level. No significant clinical or paraclinical side effects, with the exception for mild diarrhea at the beginning of treatment, were observed during 30 months therapy.
Vanadium is effective and safe for long- term use in type 1 diabetic patients.</description><identifier>ISSN: 1029-2977</identifier><identifier>EISSN: 1735-3947</identifier><identifier>PMID: 23808778</identifier><language>eng</language><publisher>Iran: Academy of Medical Sciences of I.R. Iran</publisher><subject>Adolescent ; Adult ; Blood Glucose - analysis ; Child ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - drug therapy ; Female ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Male ; Vanadium Compounds - adverse effects ; Vanadium Compounds - therapeutic use ; Young Adult</subject><ispartof>Archives of Iranian medicine, 2013-07, Vol.16 (7), p.408</ispartof><rights>Copyright Academy of Medical Sciences of I.R. Iran Jul 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23808778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soveid, Mahmood</creatorcontrib><creatorcontrib>Dehghani, Gholam Abbas</creatorcontrib><creatorcontrib>Omrani, Gholamhossein Ranjbar</creatorcontrib><title>Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes</title><title>Archives of Iranian medicine</title><addtitle>Arch Iran Med</addtitle><description>Vanadium compounds are able to reduce blood glucose in experimentally- induced diabetic rats and type 2 diabetic patients, but data about their long- term safety and efficacy in diabetic patients are scarce.
Fourteen type 1 diabetic patients received oral vanadyl sulfate (50 - 100 mg TID) for a period of 30 months. Fasting blood sugar (FBS), lipid levels, hematologic, and biochemical parameters were measured before and periodically during the treatment.
The daily doses of insulin decreased from 37.2 ± 5.5 to 25.8 ± 17.3 units/day and at the same time the mean FBS decreased from 238 ± 71 to 152 ± 42 mg/dL. Meanwhile, there was a decrease in plasma total cholesterol without any change in triglyceride level. No significant clinical or paraclinical side effects, with the exception for mild diarrhea at the beginning of treatment, were observed during 30 months therapy.
Vanadium is effective and safe for long- term use in type 1 diabetic patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Blood Glucose - analysis</subject><subject>Child</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Male</subject><subject>Vanadium Compounds - adverse effects</subject><subject>Vanadium Compounds - therapeutic use</subject><subject>Young Adult</subject><issn>1029-2977</issn><issn>1735-3947</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo1T8lKxEAUbERxxtFfkAbPgV7zuo8yuEHQi57DS_JaM5jFTkfI3xtxPFVBFbWcsK0EbTPtDZyuXCifKQ-wYRfTdBDCaCv1Odso7YQDcFv2XAz9e8YTxY5TCG2N9cKxb_iEgdLCh8C_scemnTve9jx9EE-RMHXUp18xLSNxyZsWK0o0XbKzgJ8TXR1xx97u7173j1nx8vC0vy2yUYk8ZaAlVB6I1m0hN957B7bO0ViD2lkUTjpVW1VTZWQVkEDXqgEEa6WsvNM7dvOXO8bha6YplYdhjv1aWUojvRFC6Hx1XR9dc9VRU46x7TAu5f99_QPt4lVb</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Soveid, Mahmood</creator><creator>Dehghani, Gholam Abbas</creator><creator>Omrani, Gholamhossein Ranjbar</creator><general>Academy of Medical Sciences of I.R. Iran</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201307</creationdate><title>Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes</title><author>Soveid, Mahmood ; Dehghani, Gholam Abbas ; Omrani, Gholamhossein Ranjbar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p206t-7317b97ee977f64999875c6a454a385a08182c52ceb41bfae73c2d7a75511b983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Blood Glucose - analysis</topic><topic>Child</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Male</topic><topic>Vanadium Compounds - adverse effects</topic><topic>Vanadium Compounds - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soveid, Mahmood</creatorcontrib><creatorcontrib>Dehghani, Gholam Abbas</creatorcontrib><creatorcontrib>Omrani, Gholamhossein Ranjbar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Archives of Iranian medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soveid, Mahmood</au><au>Dehghani, Gholam Abbas</au><au>Omrani, Gholamhossein Ranjbar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes</atitle><jtitle>Archives of Iranian medicine</jtitle><addtitle>Arch Iran Med</addtitle><date>2013-07</date><risdate>2013</risdate><volume>16</volume><issue>7</issue><spage>408</spage><pages>408-</pages><issn>1029-2977</issn><eissn>1735-3947</eissn><abstract>Vanadium compounds are able to reduce blood glucose in experimentally- induced diabetic rats and type 2 diabetic patients, but data about their long- term safety and efficacy in diabetic patients are scarce.
Fourteen type 1 diabetic patients received oral vanadyl sulfate (50 - 100 mg TID) for a period of 30 months. Fasting blood sugar (FBS), lipid levels, hematologic, and biochemical parameters were measured before and periodically during the treatment.
The daily doses of insulin decreased from 37.2 ± 5.5 to 25.8 ± 17.3 units/day and at the same time the mean FBS decreased from 238 ± 71 to 152 ± 42 mg/dL. Meanwhile, there was a decrease in plasma total cholesterol without any change in triglyceride level. No significant clinical or paraclinical side effects, with the exception for mild diarrhea at the beginning of treatment, were observed during 30 months therapy.
Vanadium is effective and safe for long- term use in type 1 diabetic patients.</abstract><cop>Iran</cop><pub>Academy of Medical Sciences of I.R. Iran</pub><pmid>23808778</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1029-2977 |
| ispartof | Archives of Iranian medicine, 2013-07, Vol.16 (7), p.408 |
| issn | 1029-2977 1735-3947 |
| language | eng |
| recordid | cdi_proquest_journals_1419400036 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Blood Glucose - analysis Child Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Female Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Male Vanadium Compounds - adverse effects Vanadium Compounds - therapeutic use Young Adult |
| title | Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T20%3A03%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-%20term%20efficacy%20and%20safety%20of%20vanadium%20in%20the%20treatment%20of%20type%201%20diabetes&rft.jtitle=Archives%20of%20Iranian%20medicine&rft.au=Soveid,%20Mahmood&rft.date=2013-07&rft.volume=16&rft.issue=7&rft.spage=408&rft.pages=408-&rft.issn=1029-2977&rft.eissn=1735-3947&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E3042238421%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1419400036&rft_id=info:pmid/23808778&rfr_iscdi=true |